Skip to content Loading

Free & discreet shipping on all plans

Licensed Doctors in all 50 states

Zepbound® (Injection)

Regular price  $1,089.00
Sale price  $1,089.00 Regular price 
Branded GLP-1 · Injection

Brand-name Zepbound® for weight loss

FDA-approved Zepbound® (tirzepatide) — a once-weekly dual GIP/GLP-1 pen for weight management, reviewed online by licensed U.S. providers.

FDA-approvedDual-actionBrand-name
Licensed U.S. providers
Free discreet shipping
Insurance & Medicare
Ongoing support

Overview

Zepbound® (tirzepatide) is a brand-name, FDA-approved once-weekly injection from Eli Lilly, indicated for chronic weight management. As a dual GIP/GLP-1 receptor agonist, it delivers powerful, two-pathway appetite control.

Brand-name GLP-1 weight loss delivered to your door
Brand-name care, delivered to your door

How Zepbound® works

Dual GIP + GLP-1

Activates two incretin receptors for powerful appetite control.

Curbs appetite

Reduces hunger so it is easier to eat less.

Boosts fullness

Increases satiety and supports a healthy metabolic response.

At a glance — technical specifications

Active ingredient Tirzepatide
Manufacturer Eli Lilly (brand-name)
Drug class Dual GIP & GLP-1 receptor agonist (twincretin)
What it does Indicated for chronic weight management — strong appetite control via two pathways
How it works Activates both GIP and GLP-1 receptors — reduces hunger, increases fullness
Form Prefilled injection pen
Administration Once weekly; self-injected
Dose range 2.5 mg → 15 mg (gradual titration)
FDA status FDA-approved (November 2023) for chronic weight management; also approved for moderate-to-severe obstructive sleep apnea in adults with obesity
Prescription Required — issued after licensed provider review
Storage Refrigerate 36–46°F (2–8°C); protect from light

Key benefits

Authentic brand-name, FDA-approved for weight loss
Dual GIP/GLP-1 — among the most effective in trials
Once-weekly prefilled pen
Added FDA indication for obstructive sleep apnea

The science

~20.9%

Average body-weight reduction at the 15 mg dose over 72 weeks in the SURMOUNT-1 trial; in head-to-head SURMOUNT-5, tirzepatide 15 mg reached ~20.2% vs ~13.7% for semaglutide.* Individual results vary.

FDA status

FDA-approved — Zepbound® (tirzepatide) has been FDA-approved since November 2023 for chronic weight management, with an added indication for obstructive sleep apnea in obesity.

What’s included with Mediclab

  • Review by a licensed U.S. provider (all 50 states)
  • Personalized treatment plan & titration
  • Ongoing follow-up & refills
  • Free shipping — HSA/FSA, insurance & Medicare may apply

Safety & side effects

Common effects include nausea, diarrhea, constipation, and vomiting, usually easing over time. Zepbound® carries a boxed warning regarding the risk of thyroid C-cell tumors; do not use with a personal or family history of medullary thyroid carcinoma or MEN2. Discuss any history of pancreatitis or gallbladder disease with your provider.

*SURMOUNT-1 and SURMOUNT-5 clinical trials (tirzepatide). Zepbound® is a registered trademark of Eli Lilly and Company. Mediclab is not affiliated with, sponsored by, or endorsed by the trademark owner. Prescription required; dispensed only after provider review and approval. This information is for educational purposes only and is not medical advice. Individual results vary.

Dose: 2.50 mg
In - stock and ready to ship
Start your 2-minute assessment

Prescription products require an online provider review. You pay $0 unless a licensed provider prescribes.

Free shipping

Easy return

Safe checkout

Complete The Look
Zepbound® (Injection)

Zepbound® (Injection)

Regular price  $1,089.00
Sale price  $1,089.00 Regular price 
2.50 mg
Your cart
Your cart is empty
Have an account? Log in to check out faster.
Continue shopping Continue shopping
Cart total $0.00 USD
Product image Product information Quantity Product total